Verrica Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Verrica Pharmaceuticals Inc cash flow-to-debt ratio. Verrica Pharmaceuticals Inc (VRCA) has a Cash Flow-to-Debt Ratio of -0.29x as of June 2026, meaning its operating cash flow of $-9.28 Million could theoretically repay 0% of its total liabilities ($31.71 Million) in one year. Check VRCA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Verrica Pharmaceuticals Inc (2016–2025)
Cash flow-to-debt ratio of Verrica Pharmaceuticals Inc from 2016 to 2025. Historical debt coverage capacity for Verrica Pharmaceuticals Inc across 10 annual periods. Check Verrica Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Verrica Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Verrica Pharmaceuticals Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Verrica Pharmaceuticals Inc. For the full cash flow conversion analysis, see VRCA operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.79x | $-17.63 Million | $22.39 Million | ▲ +17.3% |
| 2024 | -0.95x | $-60.93 Million | $63.99 Million | ▼ -52.6% |
| 2023 | -0.62x | $-38.58 Million | $61.83 Million | ▲ +84.3% |
| 2022 | -3.98x | $-18.65 Million | $4.69 Million | ▼ -585.4% |
| 2021 | -0.58x | $-27.58 Million | $47.52 Million | ▲ +20.9% |
| 2020 | -0.73x | $-30.21 Million | $41.17 Million | ▲ +90.9% |
| 2019 | -8.04x | $-27.41 Million | $3.41 Million | ▼ -11.4% |
| 2018 | -7.22x | $-17.87 Million | $2.48 Million | ▼ -2438.7% |
| 2017 | -0.28x | $-4.58 Million | $16.12 Million | ▲ +43.4% |
| 2016 | -0.50x | $-1.61 Million | $3.21 Million | — |